Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website http://www.jofem.org

Original Article

Volume 2, Number 6, December 2012, pages 220-227


Pentraxin 3 Levels as a Marker of Chronic Inflammation in Patients With Metabolic Syndrome

Figure

Figure 1.
Figure 1. Plasma levels of pentraxin 3 in the study groups.

Tables

Table 1. Demographic Characteristics
 
Total (n = 82)Metabolic Syndrome (n = 27)Rheumatoid Arthritis (n = 28)Control (n = 27)P
Age (Mean ± SD)46.59 ± 9.2747.70 ± 8.9245.93 ± 13.1846.18 ± 9.270.803
Gender (n (%))
  Males19 (23.2%)7 (25.9%)5 (17.9%)7 (25.9%)0.714
  Females63 (76.8%)20 (74.1%)23 (82.1%)20 (74.1%)
Smoking (n (%))9 (11%)2 (7.4%)0 (0%)7 (25.9%)0.007
Alcohol (n (%))4 (4.9%)1 (3.7%)0 (0%)3 (11.1%)0.151
Hypertension (n (%))15 (18.3%)15 (55.6%)0 (0%)0 (0%)0.001

 

Table 2. Anthropometric Characteristics (Mean ± SD)
 
Total (n = 82)Metabolic Syndrome (n = 27)Rheumatoid Arthritis (n = 28)Control (n = 27)P
BMI: Body Mass Index; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure.
Height (cm)163.24 ± 8.20165.18 ±9.26160.7 ± 8.07163.85 ± 6.730.124
Weight (kg)75.41 ± 17.1686.96 ±18.7173.39 ± 14.2565.94 ± 10.970.001
BMI (kg/m2)28.29 ± 6.0231.82 ±6.1128.51 ± 5.6724.54 ± 3.810.001
Waist circumference (cm)
  Females89.82 ± 14.7298.90 ±11.9593.00 ± 13.3877.10 ± 9.370.001
  Males94.00 ± 7.72105.57 ±8.4089.66 ± 14.5785.57 ± 7.720.005
SBP (mmHg)125.48 ±19.87140.18 ±20.12122.32 ± 16.96114.07 ±12.480.001
DBP (mmHg)81.22 ± 12.6890.56 ±12.1177.14 ± 10.1376.11 ± 10.590.001

 

Table 3. Biochemical Characteristics (Mean ± SD)
 
Total (n = 82)Metabolic Syndrome (n = 27)Rheumatoid Arthritis (n = 28)Control (n = 27)P
FPG: Fasting plazma glucose; Total-C: Total cholesterol; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; TG: Triglyceride; HOMA-IR: Homeostasis model assessment insulin resistance; Non-HDL-C: Non high density lipoprotein cholesterol; CRP: C-reactive protein.
FPG (mg/dL)90.95 ±12.9999.03 ± 11.5487.39 ± 12.8686.55 ±10.940.001
Total-C (mg/dL)222.64 ±45.76230.33 ± 50.28215.03 ± 42.74222.85 ±44.440.469
HDL-C (mg/dL)51.91 ±14.2740.92 ± 9.0957.39 ± 13.6157.22 ±13.140.001
LDL-C (mg/dL)144.74 ±37.15154.40 ± 39.06134.71 ± 33.41145.48 ±37.550.144
TG (mg/dL)155.66 ±90.54233.96 ± 90.79128.07 ± 62.42105.96 ±59.130.001
Uric acid (mg/dL)4.57 ± 1.315.29 ± 1.234.03 ± 1.274.41 ± 1.110.003
Insulin (µU/mL)7.78 ± 5.9611.60 ± 8.096.71 ± 4.075.05 ± 1.950.001
HOMA-IR1.82 ± 1.562.89 ± 2.111.47 ± 0.981.10 ± 0.520.001
Total-C/HDL-C4.53 ± 1.265.69 ± 0.853.89 ± 0.964.04 ± 1.080.001
TG/HDL-C3.45 ± 2.525.87 ± 2.282.49 ± 1.842.02 ± 1.340.001
Non-HDL-C170.73 ±43.79189.41 ± 43.80157.64 ± 39.78165.63 ±42.870.019
Sedimentation27.85 ±16.6133.44 ± 16.2432.14 ± 18.0217.78 ±10.050.001
CRP0.67 ± 1.141.01 ± 1.820.71 ± 0.680.26 ± 0.140.001
Pentraxin 30.73 ± 0.620.73 ± 0.530.70 ± 0.670.78 ± 0.650.859

 

Table 4. Post-Hoc Results of the Significantly Different Parameters
 
Metabolic Syndrome vs. Rheumatoid Arthritis (P)Metabolic Syndrome vs. Control (P)Rheumatoid Arthritis vs. Control (P)
Turkey HSD test. FPG: Fasting plazma glucose; Total-C: Total cholesterol; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; TG: Triglyceride; HOMA-IR: Homeostasis model assessment insulin resistance; Non-HDL-C: Non high density lipoprotein cholesterol; CRP: C-reactive protein.
FPG (mg/dL)0.0010.0010.963
HDL-C (mg/dL)0.0010.0010.999
TG (mg/dL)0.0010.0010.081
Uric acid (mg/dL)0.0010.0130.252
Insulin (µU/mL)0.0040.0010.216
HOMA-IR0.0010.0010.249
Total-C/HDL-C0.0010.0010.820
TG/HDL-C0.0010.0010.239
Non-HDL-C0.0180.1020.763
Sedimentation0.5010.0010.001
CRP0.4240.0010.001

 

Table 5. Correlation Between PTX 3 and the Clinical Parameters for All Cases
 
All casesPTX 3
rP
BMI: Body Mass Index; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; FPG: Fasting plazma glucose; Total-C: Total cholesterol; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; TG: Triglyceride; HOMA-IR: Homeostasis model assessment insulin resistance; Non-HDL-C: Non high density lipoprotein cholesterol; CRP: C-reactive protein.
Age0.0160.886
BMI (kg/m2)
  Females-0.0750.559
  Males-0.3390.156
Waist circumference (cm)
  Females-0.0740.565
  Males-0.0750.559
SBP (mmHg)0.0610.886
DBP (mmHg)0.1070.338
FPG (mg/dL)0.0070.949
Uric acid (mg/dL)0.0500.657
Total-C (mg/dL)-0.1260.258
LDL-C (mg/dL)-0.1090.330
TG (mg/dL)-0.1350.225
HDL-C (mg/dL)-0.0120.913
TG/HDL-C-0.0850.446
Total-C/HDL-C-0.0750.503
Non-HDL-C-0.1610.149
Insulin (µU/mL)-0.1100.324
HOMA-IR-0.1060.344
Sedimentation0.0080.943
CRP0.1210.281